Entera Bio Ltd. (ENTX)
| Market Cap | 67.98M |
| Revenue (ttm) | 482,000 |
| Net Income (ttm) | -6.48M |
| Shares Out | 28.80M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,779 |
| Open | 2.11 |
| Previous Close | 2.15 |
| Day's Range | 1.95 - 2.36 |
| 52-Week Range | 1.72 - 8.68 |
| Beta | 1.65 |
| Analysts | Buy |
| Price Target | 6.89 (+191.9%) |
| Earnings Date | May 12, 2022 |
About ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreeme...
Financial Performance
In 2021, Entera Bio's revenue was $571,000, an increase of 56.44% compared to the previous year's $365,000. Losses were -$12.19 million, 8.66% more than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for ENTX stock is "Buy." The 12-month stock price forecast is 6.89, which is an increase of 191.95% from the latest price.
News
Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights
BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and oper...
Follow the Insiders and Buy the Dip in These 3 Stocks
These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech Sto...
Entera Bio Reports Financial Results for the Year Ended December 31, 2021
— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 — — New EB612 formulation for Hypoparathyroidism trial planned in 2022 — — Oral delivery technology platform advances with more in...
Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022
BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report busin...
Entera Bio to Present at Aegis Virtual Conference on February 23rd
BOSTON and JERUSALEM, Israel, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the Comp...
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with ...
‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒ ‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒
Entera Bio Reports Third Quarter 2021 Financial Results
‒ Two Presentations at ASB M R , including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis ‒
Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs
‒Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the “Holy Grail” of drug development.
7 Biotech Penny Stocks With Huge Catalysts Coming in 2022
With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appe...
Entera Bio's Formulated Human Parathyroid Hormone Shows Encouraging BMD Data
Entera Bio Ltd (NASDAQ: ENTX) has presented the 6-month bone mineral density (BMD) data from its Phase 2 trial of EB613, an oral formulation of human parathyroid hormone (PTH), for osteoporosis. The Ph...
Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR...
Increases in lumbar spine, femoral neck and total hip BMD demonstrated with EB613
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Mee...
‒ Second of Two Presentations to be Delivered by Entera ‒
Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annu...
Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company's CEO Spi...
New Strong Sell Stocks for August 19th
ALIM, BEEM, CDR, ENTX, and IDEX have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2021.
Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates
‒ Phase 2 EB613 Clinical Trial in Osteoporosi s Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met ‒
Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021
BOSTON and JERUSALEM, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and...
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone...
‒ The Study's Primary Endpoint was Met; P1NP, a Biochemical Marker of Bone Formation, was Significantly Increased at Month 3 in EB613 2.5 mg Treatment Group Versus Placebo ‒
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral...
BOSTON and JERUSALEM, June 28, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a con...
Entera (ENTX) Up on Positive Results From Osteoporosis Drug
Entera (ENTX) gains on positive results from a mid-stage study on its osteoporosis candidate at six months.
Where Might Entera Bio Stock End Up After Rallying Wednesday
Entera Bio Ltd (NASDAQ: ENTX) shares rallied higher Wednesday after the company announced it saw positive results from its final six-month bone mineral density results from the completed Phase 2 clinica...
ENTX Stock: The Huge FDA News Sending Entera Bio Soaring
Today, investors in ENTX stock are seeing gains of approximately 40% as the company announced results from one of its clinical trials. The post ENTX Stock: The Huge FDA News Sending Entera Bio Soaring a...
Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday.
Why Entera Bio Shares Are Skyrocketing Today
Entera Bio Ltd (NASDAQ: ENTX) shares are trading higher by 47.66% at $6.63 Wednesday after the company announced the topline Phase 2 clinical trial of EB613 met its primary and key secondary endpoints. ...